{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Phase+I&page=16", "query": { "condition": "Phase I", "page": 16 }, "page_size": 10 }, "pagination": { "page": 16, "page_size": 10, "total_count": 18744, "total_pages": 1875, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Phase+I&page=17&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Phase+I&page=15&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-10T04:33:53.089Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03486314", "title": "A Study to Evaluate the Effects of Rifampin on Pharmacokinetics (PK) of Pevonedistat in Participants With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Neoplasm" ], "interventions": [ { "name": "Pevonedistat", "type": "DRUG" }, { "name": "Rifampin", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Millennium Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2018-08-13", "completion_date": "2021-02-28", "has_results": true, "last_update_posted_date": "2022-04-18", "last_synced_at": "2026-11-10T04:33:53.089Z", "location_count": 4, "location_summary": "Atlanta, Georgia • Chicago, Illinois • Detroit, Michigan + 1 more", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Greenville", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03486314" }, { "nct_id": "NCT04009681", "title": "A Study Evaluating Safety and Therapeutic Activity of THOR-707 in Adult Subjects With Advanced or Metastatic Solid Tumors (THOR-707-101)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastasis" ], "interventions": [ { "name": "THOR-707", "type": "DRUG" }, { "name": "Checkpoint inhibitor", "type": "DRUG" }, { "name": "anti-EGFR antibody", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Synthorx, Inc, a Sanofi company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 175, "start_date": "2019-06-20", "completion_date": "2025-12-02", "has_results": false, "last_update_posted_date": "2025-12-15", "last_synced_at": "2026-11-10T04:33:53.089Z", "location_count": 7, "location_summary": "Scottsdale, Arizona • Denver, Colorado • Sarasota, Florida + 4 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Denver", "state": "Colorado" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04009681" }, { "nct_id": "NCT04750928", "title": "Cyclin-Dependent Kinase (CDK)4/6 Inhibitor Abemaciclib for Neurofibromatosis Type I (NF1) Related Atypical Neurofibromas", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Neurofibromatosis 1" ], "interventions": [ { "name": "Abemaciclib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 55, "start_date": "2021-11-29", "completion_date": "2029-12-31", "has_results": false, "last_update_posted_date": "2026-10-16", "last_synced_at": "2026-11-10T04:33:53.089Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04750928" }, { "nct_id": "NCT01723800", "title": "PI3K Inhibitor BKM120, Carboplatin, and Pemetrexed Disodium in Treating Patients With Stage IV Non-Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent Non-small Cell Lung Cancer", "Stage IV Non-small Cell Lung Cancer" ], "interventions": [ { "name": "PI3K inhibitor BKM120", "type": "DRUG" }, { "name": "pemetrexed disodium", "type": "DRUG" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "pharmacological study", "type": "OTHER" }, { "name": "quality-of-life assessment", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "OTHER", "PROCEDURE" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 9, "start_date": "2013-07", "completion_date": "2016-09", "has_results": false, "last_update_posted_date": "2016-09-20", "last_synced_at": "2026-11-10T04:33:53.089Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01723800" }, { "nct_id": "NCT00161707", "title": "Safety Study of an Aerosolized, Recombinant Alpha 1-Antitrypsin in Subjects With Alpha 1-Antitrypsin Deficiency", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Alpha1-antitrypsin Deficiency" ], "interventions": [ { "name": "Aerosolized, Recombinant Alpha 1-Antitrypsin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Baxalta now part of Shire", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2003-01-07", "completion_date": "2003-10-01", "has_results": false, "last_update_posted_date": "2021-05-05", "last_synced_at": "2026-11-10T04:33:53.089Z", "location_count": 4, "location_summary": "Denver, Colorado • Gainesville, Florida • Cleveland, Ohio + 1 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Tyler", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00161707" }, { "nct_id": "NCT01130844", "title": "Safety and Pharmacokinetics of MMX Mesalamine in Children and Adolescents With Ulcerative Colitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Ulcerative Colitis" ], "interventions": [ { "name": "MMX Mesalamine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Shire", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "5 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "5 Years to 17 Years" }, "enrollment_count": 52, "start_date": "2010-10-08", "completion_date": "2013-06-27", "has_results": true, "last_update_posted_date": "2021-06-14", "last_synced_at": "2026-11-10T04:33:53.089Z", "location_count": 6, "location_summary": "Little Rock, Arkansas • Anaheim, California • San Francisco, California + 3 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Hartford", "state": "Connecticut" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01130844" }, { "nct_id": "NCT00005898", "title": "Phase I/II Study of Total Body Irradiation, Cyclophosphamide, and Fludarabine Followed by Alternate Donor Hematopoietic Cell Transplantation in Patients With Fanconi's Anemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Fanconi's Anemia" ], "interventions": [ { "name": "anti-thymocyte globulin", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "cyclosporine", "type": "DRUG" }, { "name": "filgrastim", "type": "DRUG" }, { "name": "fludarabine", "type": "DRUG" }, { "name": "methylprednisolone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "0 Years", "maximum_age": "34 Years", "sex": "ALL", "summary": "0 Years to 34 Years" }, "enrollment_count": 30, "start_date": "2000-02", "completion_date": null, "has_results": false, "last_update_posted_date": "2005-06-24", "last_synced_at": "2026-11-10T04:33:53.089Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00005898" }, { "nct_id": "NCT00000806", "title": "A Phase I Randomized Dose/Formulation Comparison Study of SC-52151", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Telinavir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "ALL", "summary": "21 Years and older" }, "enrollment_count": 48, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2005-06-24", "last_synced_at": "2026-11-10T04:33:53.089Z", "location_count": 4, "location_summary": "San Diego, California • Miami, Florida • Baltimore, Maryland + 1 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00000806" }, { "nct_id": "NCT06036784", "title": "Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of MBX 1416 in Healthy Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Postbariatric Hypoglycemia" ], "interventions": [ { "name": "MBX 1416 (Part A)", "type": "DRUG" }, { "name": "MBX 1416 (Part B)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "MBX 1416 (Part C)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "MBX Biosciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 69, "start_date": "2023-09-18", "completion_date": "2024-12-05", "has_results": false, "last_update_posted_date": "2024-12-12", "last_synced_at": "2026-11-10T04:33:53.089Z", "location_count": 1, "location_summary": "Chula Vista, California", "locations": [ { "city": "Chula Vista", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06036784" }, { "nct_id": "NCT00282581", "title": "Safety Study of MVA Smallpox Vaccine in HIV-positive Subjects Who Are Vaccinia Naive", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections", "Smallpox" ], "interventions": [ { "name": "MVA Smallpox Vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Sanofi Pasteur, a Sanofi Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "35 Years", "sex": "ALL", "summary": "18 Years to 35 Years" }, "enrollment_count": 2, "start_date": "2006-10", "completion_date": "2007-07", "has_results": false, "last_update_posted_date": "2014-01-22", "last_synced_at": "2026-11-10T04:33:53.089Z", "location_count": 6, "location_summary": "Birmingham, Alabama • Los Angeles, California • San Francisco, California + 2 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00282581" } ] }